Business Context and Reporting Period
This Form 8-K is a current report filed by PharmAthene, Inc. on March 11, 2016. The filing serves to announce the company's financial and operational results for the fiscal year ended December 31, 2016. The report references a press release furnished as Exhibit 99.1 containing the detailed results.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the attached press release (Exhibit 99.1), which is not included in the source text.
Material Changes
The filing does not provide specific data regarding material changes versus prior periods. It only confirms the issuance of results for the fiscal year ended December 31, 2016.
Guidance, Outlook, and Risks
The text does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies. It notes that the information in this report and the attached press release is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) in the press release dated March 11, 2016 (Exhibit 99.1), as they are not listed in this 8-K summary.
- Confirm the fiscal year end date is December 31, 2016, as stated in the announcement.
- Note that the registrant is PharmAthene, Inc., not Altimmune, Inc., despite the metadata request.
- Review the full press release for any operational milestones or clinical trial updates that may accompany the financial results.